Skip to main content

Tweets

UAB study shows the US adult rheumatology workforce grew clinically active adult rheumatology workforce grew 23% betw 2009-2020; including a 43% increase in women. Number of Rheums (5,667) grew 23% and APPs (379) grew 141%. https://t.co/sVPoNIUZUu https://t.co/4myGYaUtcd
Dr. John Cush @RheumNow ( View Tweet )
2 hours 26 minutes ago
US Trends in RA DMARD Use 2017-2021 A trend analysis of disease-modifying anti-rheumatic drugs (DMARDs) shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. https://t.co/vQmVyAjIaL https://t.co/tSJ4H5XtnU
Dr. John Cush @RheumNow ( View Tweet )
4 hours 27 minutes ago
MMWR: Vaccination and Multisystem Inflammatory Syndrome in Children MIS-C is a rare but serious condition typically occurring 2–6 weeks after SARS-CoV-2 infection and characterized by fever and multiorgan involvement. https://t.co/PN2MPQxqSR https://t.co/eIzB4pjner
Dr. John Cush @RheumNow ( View Tweet )
5 hours 26 minutes ago
In RA, NO selective response with Seropositivity. Study of 28 eligible RCTs shows pts Rx w/ cs- or bDMARD that seropositivity did not predict better bDMARD response (ACR20 RRR ~1). Comparable resp in RF+ & RF- w/ TNFi or non-TNFi bDMARDs. https://t.co/AUWPgkzayt https://t.co/om9AYhNsQ9
Dr. John Cush @RheumNow ( View Tweet )
9 hours 26 minutes ago
9 Facts about Leflunomide Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. https://t.co/X9lyrOs3D7 https://t.co/TGh2LnGdJ8
Dr. John Cush @RheumNow ( View Tweet )
11 hours 26 minutes ago
Retro study 109 oligoarticular JIA pts (~8 yrs) Rx w/ intraarticular steroids w/ 4.3 yrs F/U: 38% needed no Rx, 15.5% needed more IAS; 46% systemic Rx(MTX; 8 mos) &22% biologics(2.2 yrs later). @FUV 89% were inactive. Persistence predicted by ANA+ & B27+ https://t.co/5YLkYyA84l https://t.co/wClhEiKOIw
Dr. John Cush @RheumNow ( View Tweet )
13 hours 26 minutes ago
Japanese study of 672 autoimmune pts on TNFi & tocilizumab - 1.6% (n=9) developed non-tuberculous Mycobacteria (NTM) infx post biologics. 2 disseminated NTM, 2 died. NTM pts had higher mortality [(22% vs 2.6%) & took more steroid (17 vs 3 mg, P=0.004).https://t.co/fGGafrTeiL https://t.co/DkmiC2hVEA
Dr. John Cush @RheumNow ( View Tweet )
1 day 7 hours ago
JAMA Review of DMARD Use in Rheumatoid Arthritis JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs". https://t.co/fpAigPpKzv https://t.co/GkbqW2BxpA
Dr. John Cush @RheumNow ( View Tweet )
1 day 11 hours ago
JAK-pot: 46913 Rx courses on JAKi, TNFi, other MOA. Rx D/Cs for AEs: - TNFi = JAKi (HR 1.0) - Other MOA > JAKi (HR 1.11) - TNFi < tofacitinib (0.81) - TNFi > baricitinib (1.15) - TNFi < JAKi; if >65yrs w/ CV risk (0.79) https://t.co/jCtLG3SNvP https://t.co/FN5U5Z1M9M
Dr. John Cush @RheumNow ( View Tweet )
1 day 13 hours ago
Effective Treatments for Still's Disease A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK). https://t.co/r7RGD5WlvO https://t.co/Jfq7zPR0ci
Dr. John Cush @RheumNow ( View Tweet )
2 days 5 hours ago
JAK inhibitors maybe an option in refractory Juvenile Dermatomyositis. Metanalysis of 26 reports (195 pts) JDM Rx w/ JAKi (median 5 rys); most Rx w/ tofacitinib (57%), ruxolitinib(27%), baricitinib (15%), w/ Improvement in 90%, 69%, 93%, respectively. https://t.co/tfISYVtwUN https://t.co/zv88Vdy6c0
Dr. John Cush @RheumNow ( View Tweet )
2 days 5 hours ago
Again, a High Mortality with Depression and RA Last week we reported on a Korean study showing a 66% elevated mortality risk in RA patients with depression. This week, a new report shows depression in RA increases the mortality risk by more than 5 fold. https://t.co/C7Z7djny4S https://t.co/J9B6DUqcIC
Dr. John Cush @RheumNow ( View Tweet )
3 days 11 hours ago